What Our Client Needed
The head of commercial strategy & innovation at a mid-size pharma company required external support with evaluating potential acquisition targets in the oncology disease space to help inform decision-making and potential deal terms.
Aquilae CG’s experience in the oncology disease space, ability to assess the future commercial potential associated with the portfolio of target companies, and willingness to act as “devil’s advocate” around key strategic issues were highly valued by the client.
Aquilae CG conducted a robust analysis and developed several forecasting models to estimate the future commercial opportunity and corresponding cash flow associated with the products of target companies.
In addition, we highlighted key strategic considerations influencing decision-making, which included potential corporate synergies, opportunity costs of acquisition, and value of broader presence in specific niches in oncology.
Our analysis clearly articulated the strong rationale to acquisition one lead target company given the company’s strategic fit with our client’s organization. Our client decided to seize this opportunity resulting in a >$1 billion acquisition.
Aquilae CG has continued to provide support services, including portfolio prioritization, to the organization during the integration phase after the successful acquisition.